Cargando…

Molecular docking analysis of FDA approved drugs with the glycoprotein from Junin and Machupo viruses

Arenaviruses, Junin and Machupo are pathogenic viruses in regions of South America including Argentina and Bolivia causing haemorrhagic fever among humans. They have been transmitted to humans through mouse causing chronic illness with high mortality. Therefore, it is of interest to acquittance the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malhotra, Himani, Kumar, Arvind, Afaq, Yasir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Biomedical Informatics 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649494/ https://www.ncbi.nlm.nih.gov/pubmed/36420432 http://dx.doi.org/10.6026/97320630018119

Ejemplares similares

The Ectodomain of Glycoprotein from the Candid#1 Vaccine Strain of Junin Virus Rendered Machupo Virus Partially Attenuated in Mice Lacking IFN-αβ/γ Receptor
por: Koma, Takaaki, et al.
Publicado: (2016)

Tuning the binding interface between Machupo virus glycoprotein and human transferrin receptor
por: Sjöström, Dick J, et al.
Publicado: (2020)

Machupo Virus Glycoprotein Determinants for Human Transferrin Receptor 1 Binding and Cell Entry
por: Radoshitzky, Sheli R., et al.
Publicado: (2011)

Molecular docking of monkeypox (mpox) virus proteinase with FDA approved lead molecules
por: Arasu, M.Valan, et al.
Publicado: (2023)

Analyzing machupo virus-receptor binding by molecular dynamics simulations
por: Meyer, Austin G., et al.
Publicado: (2014)

Exploration of Potential Ewing Sarcoma Drugs from FDA-Approved Pharmaceuticals through Computational Drug Repositioning, Pharmacogenomics, Molecular Docking, and MD Simulation Studies
por: Hassan, Mubashir, et al.
Publicado: (2022)

Isolation of Reconstructed Functional Ribonucleoprotein Complexes of Machupo Virus
por: Pyle, Jesse D., et al.
Publicado: (2021)

Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer
por: Yoon, Sungpil, et al.
Publicado: (2021)

Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus
por: Odhar, Hasanain Abdulhameed, et al.
Publicado: (2020)

Molecular docking-based screening of methicillin-resistant Staphylococcus aureus FEM proteins with FDA-approved drugs
por: Akkiraju, Anjini Gayatri, et al.
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Junín Virus Pathogenesis and Virus Replication
por: Grant, Ashley, et al.
Publicado: (2012)

Structure of Machupo virus polymerase in complex with matrix protein Z
por: Ma, Jun, et al.
Publicado: (2021)

Molecular docking and dynamics simulation analysis of nucleoprotein from the Crimea-Congo hemorrhagic fever virus strain Baghdad-12 with FDA approved drugs
por: Hashim, Ahmed Fadhil, et al.
Publicado: (2022)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

The entry of Junin virus into Vero cells
por: Castilla, V., et al.
Publicado: (1994)

Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics
por: Lai, Jiun-I, et al.
Publicado: (2020)

Possible FDA-approved drugs to treat Ebola virus infection
por: Yuan, Shu
Publicado: (2015)

A STAT-1 knockout mouse model for Machupo virus pathogenesis
por: Bradfute, Steven B, et al.
Publicado: (2011)

RNA ligands activate the Machupo virus polymerase and guide promoter usage
por: Pyle, Jesse D., et al.
Publicado: (2019)

Computation screening and molecular docking of FDA approved viral protease inhibitors as a potential drug against COVID-19
por: Absalan, Abdorrahim, et al.
Publicado: (2020)

Development of a Reverse Genetic System to Generate Recombinant Chimeric Tacaribe Virus that Expresses Junín Virus Glycoproteins
por: Foscaldi, Sabrina, et al.
Publicado: (2020)

Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection
por: Wang, Shaobo, et al.
Publicado: (2017)

The Virus–Host Interplay in Junín Mammarenavirus Infection
por: Gallo, Giovanna Lucrecia, et al.
Publicado: (2022)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

In Silico Study towards Repositioning of FDA-Approved Drug Candidates for Anticoronaviral Therapy: Molecular Docking, Molecular Dynamics and Binding Free Energy Calculations
por: Qayed, Wesam S., et al.
Publicado: (2022)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

In silico identification of potential inhibitors of vital monkeypox virus proteins from FDA approved drugs
por: Sahoo, Ajaya Kumar, et al.
Publicado: (2022)

A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus
por: Ekins, Sean, et al.
Publicado: (2014)

Expression and Purification of Z Protein from Junín Virus
por: Goñi, S. E., et al.
Publicado: (2010)

Inhibition of Junín virus replication by small interfering RNAs
por: Artuso, María C., et al.
Publicado: (2009)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2
por: Anwaar, Muhammad U., et al.
Publicado: (2022)

Potential Inhibitors of SARS-CoV-2 Main Protease (M(pro)) Identified from the Library of FDA-Approved Drugs Using Molecular Docking Studies
por: Verma, Dipesh Kumar, et al.
Publicado: (2022)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b5244trkdtbemkn0h2l006ldn0